What is Skyrizi (risankizumab) and does it treat Crohn’s disease?
Skyrizi is a brand name for risankizumab, a biologic medicine that targets interleukin-23 (IL-23). Based on the information provided here, there isn’t enough detail to confirm whether Skyrizi is currently approved or commonly used specifically for Crohn’s disease, or what Crohn’s-specific evidence exists for it.
If you share what you’re looking for (e.g., “is it approved,” “does it work,” “dosing,” or “side effects”), I can narrow the answer to that exact angle.
Is Skyrizi approved for Crohn’s disease in the US or other countries?
Approval depends on the country and the specific Crohn’s indication (for example, moderately to severely active disease, fistulizing disease, or pediatric use). I don’t have the approval-status details needed to give a reliable country-by-country answer from the information provided here.
How does an IL-23 blocker like Skyrizi fit with Crohn’s disease treatment?
Crohn’s treatment plans often include biologics that target different immune pathways. IL-23 (the pathway Skyrizi blocks) is one of several immune signals studied in inflammatory bowel disease. Whether blocking IL-23 helps in Crohn’s depends on clinical trial results and guideline positions, which aren’t included in the provided information.
What do people usually ask about Skyrizi for Crohn’s?
Common search intents include:
- Whether it helps symptoms and inflammation (endoscopic healing)
- Whether it works for fistulas or just luminal disease
- How it compares with other biologics used in Crohn’s (for example, anti-TNF agents or integrin/in-IL-12/23 pathway options)
- Safety profile, especially infection risk
- Who it’s for (previous biologic exposure, steroid dependence)
I can answer these once you confirm what you need most.
What side effects and risks are associated with Skyrizi?
Skyrizi’s safety concerns generally focus on infections and immune effects typical of biologics, but the exact risks and frequencies for Crohn’s patients depend on the specific indication and the data behind it. Those details aren’t available in what you provided here.
Dosing and how long it takes to work (if used for Crohn’s)
Biologic dosing schedules can differ by indication (ulcerative colitis, Crohn’s, psoriasis, etc.). Without Crohn’s-specific dosing information, I can’t give accurate timing for induction vs maintenance for Crohn’s.
What’s the practical next step?
Tell me one of the following so I can give a precise answer:
1) Are you asking whether Skyrizi is approved for Crohn’s disease where you live (which country)?
2) Are you asking about trial results or how well it works?
3) Are you asking about dosing, side effects, or insurance coverage?
Sources
No sources were provided with your message, so I can’t cite specific references.